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Abstract. Two new vascular smooth muscle
relaxants, bepridil and cetiedil, were found to possess
specific CaM-inhibitory properties which resembled those
of trifluoperazine. Trifluoperazine, bepridil, and cetiedil
inhibited Ca2+-dependent '251-CaM binding to erythro-
cyte membranes and CaM activation of membrane
Ca2+-ATPase with IC50 values of -12, 17, and -40
MAM, respectively. This does not appear to be the result
of a nonspecific hydrophobic interaction since inhibition
was not observed with micromolar concentrations of
many other hydrophobic agents. The predominant in-
hibition of binding and Ca2+-ATPase activation was
competitive with respect to CaM. Bepridil and cetiedil
bind directly to CaM since these drugs displaced
[3H]trifluoperazine from sites on CaM. Inhibition of
Ca2+-ATPase and binding by the drugs was not due to
interference with the catalytic activity of this enzyme
since: (a) neither inhibition of CaM-independent basal
Ca2+-ATPase activity nor inhibition of proteolytically-
activated Ca2+-ATPase activities were produced by these
agents, and (b) no drug-induced inhibition of CaM
binding was detected when membranes were preincu-
bated with these agents but washed prior to addition of
I25I-CaM.
Thus, bepridil and cetiedil competitively inhibit Ca2+_
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dependent interactions of CaM with erythrocyte mem-
branes, most likely by a direct interaction between these
drugs and CaM. The principal clinical actions of these
drugs may be explained by their interactions with CaM
or CaM-related proteins leading to reduced activation
of Ca2"-regulated enzymes in certain other tissues, such
as myosin light chain kinase in vascular smooth muscle.
Introduction
Calmodulin (CaM)' is a ubiquitous 17,000 Mr intracellular
Ca2"-binding protein known to activate many Ca2"-dependent
enzymes and thereby plays a fundamental role in regulation
of many physiological events (see monograph, 1, and reviews
2-5). All tissues contain large amounts of CaM ( 10-6 M)
(6), and the list of known CaM-regulated processes is no doubt
far from complete. Trifluoperazine and other phenothiazines
inactivate CaM (7) by binding to specific sites on CaM in a
Ca2"-dependent manner (8). It has been argued that these
represent nonspecific hydrophobic interactions rather than true
pharmacologic antagonism (9, 10). However, several neuroleptic
drugs and other classes of drugs have been shown to bind
directly to CaM and specifically antagonize its effects (11, 12),
and relationships between drug structure and inhibition have
been established (13, 14). No clinically employed drug is
presently known to exert its principal pharmacologically desired
effects by binding to CaM, although this is an active area of
investigation (15).
Clinical medicine is presently experiencing an explosion of
interest in use of Ca2" antagonists for the treatment of cardio-
vascular diseases (see monograph 16, and review 17). Two
classes of Ca2" channel blocking drugs are currently used in
clinical practice in the United States: "use-dependent" agents
(verapamil and diltiazem) and direct channel "plugs" (nifedi-
pine). Two vascular smooth muscle relaxants, bepridil and
cetiedil, are currently used in Europe to treat angina and
claudication, and these drugs produce some effects similar to
the Ca2"-channel blocking agents. Some differences between
1. Abbreviations used in this paper: CaM, calmodulin; '251-CaM, 125i-
Bolton Hunter reagent-labeled erythrocyte calmodulin.
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the recognized Ca2"-channel blockers and bepridil and cetiedil
include: (a) much higher concentrations of bepridil and cetiedil
are required, (b) the electrophysiologic effects are distinct, and
(c) bepridil and cetiedil both produce effects on a wide range
of other tissues. Despite investigation of bepridil and cetiedil
in several laboratories, the biochemical mechanisms of their
actions are unknown.
This report describes the use of a recently developed
erythrocyte system for identification and evaluation of potential
CaM-inhibitors (18, 19). It was found that bepridil and cetiedil
competitively inhibit Ca2+-dependent CaM binding to mem-
brane receptor sites and displace trifluoperazine from sites on
CaM, probably by directly interacting with CaM. The princi-
pally desired pharmacologic effect, relaxation of vascular smooth
muscle, and possibly effects upon other tissues are probably
sequelae of inhibition of CaM-dependent enzymes.
Methods
Reagents. Bepridil, #-42-methylpropoxy)methyl-N-phenyl-N4phenyl-
methyl)-1-pyrrolidineethanamine monohydrochloride monohydrate and
cetiedil, 2-hexahydro-1H-azepin-1-yl)ethyl a-cyclohexyl-3-thiophenac-
etate 2-hydroxy-1,2,3-propanetricarboxylate hydrate (1:1:1) were pro-
vided by McNeil Pharmaceutical (Spring House, PA). Other drugs
from a variety of industrial sources were provided by Dr. Robert
Gould, Department of Neurosciences, Johns Hopkins Medical School.
'25I-Bolton Hunter reagent was from Amersham Corp., Arlington
Heights, IL; (y-32P)ATP (-25 Ci/mmol) was from ICN Radiochemicals,
Irvine, CA; [3H]trifluoperazine (72 Ci/mmol) was from New England
Nuclear, Boston, MA; a-chymotrypsin (54 u./mg) was from Millipore,
Bedford, MA; ultra pure sucrose was from Schwarz/Mann; NaEGTA,
ouabain, trifluoperazine, phenylmethylsulfonyl fluoride, dithiothreitol,
and Norit A were from Sigma Chemical Co., St. Louis, MO; Hepes
was from Research Organics, Inc., Cleveland, OH; and other reagent
grade chemicals were used. Pure erythrocyte CaM was prepared and
radiolabeled to -70,000 cpm/pmol with '25I-Bolton Hunter reagent
as described (19).
Membrane -preparations. Blood was obtained from normal adult
volunteers by venipuncture, anticoagulated with acid citrate dextrose,
and stored for up to 3 d at 0°C. Erythrocyte ghost membranes were
prepared from erythrocytes washed three times in 0.15 M NaCl, 5 mM
NaPO4, pH 7.4, and lysed in 40 vol of ice-cold 7.5 mM NaPO4, 1
mM NaEGTA, 35 Ag/ml phenylmethylsulfonyl fluoride, pH 7.3,
centrifuged at 44,000 g for 10 min and washed repetitively until white.
The membranes were then washed once in 10 mM Hepes, pH 7.3,
and stored at 0°C in 10 mM Hepes, pH 7.3, 0.1 mM dithiothreitol, I
mM NaN3 for up to I d. Spectrin-actin stripped membrane vesicles
were prepared by incubating fresh ghost membranes in 40 vol of 0.3
mM NaPO4, pH 7.4, at 37°C for 30 min. The vesicles were pelleted
at 44,000 g for 25 min, washed again in 10 mM Hepes, pH 7.3, and
resuspended to 1.5 mg protein/ml in 10 mM Hepes, 0.1 mM dithio-
threitol, I mM NaN3. a-chymotrypsin-digested vesicles were prepared
basically as described (19). Spectrin-actin stripped membrane vesicles
(1.5 mg protein/ml) were incubated for 45 min at 0°C with 8 Ag/ml
a-chymotrypsin (diluted from a fresh stock solution of 4 mg a-
chymotrypsin in I ml of 2 mM HCI), then washed twice in ice cold
10 mM Hepes (pH 7.3) also containing 50 tg/ml phenylmethylsulfonyl
fluoride, and resuspended to 1.2 mg protein/ml in 10 mM Hepes, 0.1
mM dithiothreitol, I mM NaN3.
Binding assay. Inhibition of Ca2"-dependent '2'I-Bolton Hunter
reagent-labeled erythrocyte calmodulin ('251I-CaM) binding to erythrocyte
ghost membranes was measured as described (19). Glass tubes were
employed due to adherence of some drugs to plastic. Generally
trifluoperazine, bepridil, cetiedil, or other drugs were freshly dissolved
to -0.5 mM in distilled water, and dilutions were added to '251I-CaM
(0.3-10 nM diluted in 0.25 mg/ml gelatin) in 80 mM NaCI, 30 mM
KC1, 0.5 mM MgCI2, 30 mM Hepes (pH 7.3) either with buffered
Ca2+ (2.50 mM CaC12/2.50 mM NaEGTA, pCa2+ = 5.0) or chelator
(2.50 mM NaEGTA, pCa2' > 8). Erythrocyte ghost membranes were
added last to a final volume of 0.2 ml, and incubations were performed
at room temperature until binding equilibrium was established (4-5
h). Specific membrane binding was determined by layering 0.18-ml
aliquots over a small airspace above 0.2 ml of the same buffer
containing 20% (wt/vol) sucrose in hard polyethylene Eppendorf
microtest tubes. The tubes were spun at 35,000g for 30 min and
frozen in crushed dry ice. The tips (containing '25I-CaM bound to
membranes) were clipped off and assayed for 1251 in a gamma counter.
The tops (containing unbound '25I-CaM) were likewise assayed. Ca2+-
dependent membrane binding was determined by subtracting counts
per minute from tips of parallel incubations under identical conditions
wherein NaEGTA was included without CaC12. Duplicate values in
the binding assay were within 5%.
Ca2i-ATPase assay. Analysis of Ca2+-dependent ATP hydrolysis
was measured basically as described (19). Freshly dissolved drugs,
unlabeled pure erythrocyte CaM, and erythrocyte membranes were
incubated exactly as described for the binding assay also including 0.1
mM ouabain. After binding equilibrium was established, (,y-32P)ATP
was added for 30 min at room temperature and the reaction was
stopped during the linear stage of ATP hydrolysis by addition of 1.0
ml of ice-cold 10% (wt/vol) trichloroacetic acid followed by 0.5 ml of
10% (wt/vol) Norit A. The tubes were centrifuged 3000 g for 10 min
and l.0-ml aliquots of the supernatant (free Pj) were assayed for 32p
in a liquid scintillation counter after addition of 5 ml Beckman Ready-
Solv (Beckman Instruments, Inc., Fullerton, CA). Background Pi levels
were subtracted (counts per minute measured without Ca2+ or without
membranes). Duplicate determinations were within 5%.
Results
Bepridil and cetiedil inhibit Cai-dependent CaM-binding to
membranes. CaM associations with erythrocyte membranes
have been analyzed with a binding assay employing '25I-labeled
CaM (18, 19). The Ca2+-transporter (Ca2+-ATPase) is a principal
high affinity CaM binding site on the membrane (Kd < 10-9
M), and associations with additional membrane sites are also
measured with this probe (19). This relatively simple and
highly reproducible assay will permit rapid analysis of many
different agents for ability to inhibit '25I-CaM binding to these
sites. Effects of drugs upon unlabeled CaM may be evaluated
by measurement of Ca2+-ATPase activation. Erythrocyte Ca2`-
ATPase has been purified and well-defined biochemically (20).
A similar enzyme is present in other tissues (21), and therefore,
results with erythrocytes are likely to have more general
significance. Phenothiazines (22) and certain classes of exper-
imental drugs (23) inhibit a variety of CaM-dependent enzymes
by directly interacting with CaM. Trifluoperazine at - 10-4 M
was found both to inhibit and reverse Ca2+-dependent 1251_
CaM binding to sites on erythrocyte membranes (19). Many
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different hydrophobic drugs from several therapeutic classes
were evaluated for ability to inhibit 125I.CaM binding. Negligible
inhibition of 10 nM '25I-CaM binding was observed with 100
MM concentrations of the following drugs: nifedipine, neover-
apamil, diltiazem, papaverine, quinidine, procainamide, lido-
caine, phenytoin, ouabain, atropine, phentolamine, propranolol,
yohimbine, reserpine, isoproterenol, arecoline, aminophylline,
dibucaine, doxepin, mesoridazine, diazepam, spiperone, di-
phenhydramine, cimetidine, colchicine, indomethacin, chlo-
roquine, cinchonine, berberine, cytochalasin, boldine, and
aconitine. However, two vascular smooth muscle relaxants,
bepridcil and cetiedil (Fig. 1), were found to be potent antagonists
of Ca2'-dependent '25I-CaM binding. Both drugs at 50 #M
reduced binding of 10 nM '251-CaM by >50%, whereas many
other hydrophobic drugs (including several Ca2' channel
blockers) failed to interfere significantly with '251I-CaM binding.
Reduction in Ca2'-dependent '251I-CaM binding produced by
50 IMM bepridil and cetiedil do not result from reductions in
free Ca2+ concentrations due to chelation of Ca2+ by these
drugs, since 2.50 mM CaC12/2.50 mM EGTA will buffer
against such effects. Bepridil and cetiedil are known to block
several Ca2+-dependent physiologic effects in a variety of
tissues. Furthermore, these compounds have structural features
previously identified as important for binding to CaM (13): a
hydrophobic aromatic ring system with a flexible side chain
containing an amino group which should be positively charged
at physiologic pH. It was considered possible that inhibition
of CaM may be the basis for some of these effects, so specific
actions ofbepridil and cetiedil upon CaM binding to erythrocyte











Figure 1. Structures of trifluo-
perazine, cetiedil, and bepridil.
Inhibition of binding and Ca2+-ATPase is predominantly
competitive with respect to CaM. Inhibition of Ca2'-dependent
CaM-binding may result from direct interaction of drugs with
CaM (leading to inactivation of CaM) or by reversible inter-
actions of drugs directly with CaM binding sites on the
membrane. Both types of interactions should be competitive
with respect to CaM. Inhibition may also result from interaction
of drugs with other sites on the membrane, which create
secondary effects upon the CaM binding sites, or by irreversible
damage to the binding site (noncompetitive inhibition). To
distinguish competitive from noncompetitive interactions, in-
hibition of '25I-CaM binding and activation of Ca2'-ATPase
were measured at multiple CaM concentrations. Binding of
0.3, 0.8, and 2 nM '251I-CaM was inhibited by trifluoperazine,
bepridil, and cetiedil with inhibitory concentration of 50%
(IC30) values of 10-12, 14-19, and 32-39 MAM, respectively
(Fig. 2). Competitive inhibition is best analyzed with Dixon
plots (24) wherein the reciprocals of enzyme activation (or
binding) at two or more concentrations of a specific ligand are
plotted against increasing concentrations of inhibitor. In simple
bimolecular interactions, the plots are linear and extrapolations
intersect at inhibitor concentrations corresponding to negative
inhibition constant (K,). Precise determinations of the K, were
not possible in these experiments since Dixon plots (not
shown) were parabola-shaped at these drug concentrations.
Nonlinear Dixon plots suggest that the drug-CaM inhibition
may be complex (possibly cooperative). Double reciprocal
plots of these data are shown as inserts in Fig. 2. The principal
inhibition by all three agents is competitive with respect to
CaM. Linear regressions have increasing slopes at increasing
drug concentrations, and each clearly projects to a different
point on the x axis (l/Kd). As expected for a competitive
inhibition, the projections intersect the y axis at nearly the
same point, the reciprocal of the expected high affinity binding
capacity, -10 pmol/mg membrane protein (19). However,
projections at the higher drug concentrations (30 $&M trifluo-
perazine, >30 MM bepridil, and >45 AM cetiedil) intersect the
y axis at slightly higher points indicating that secondary
noncompetitive interactions may also occur.
Basal and CaM-stimulated Ca2+-ATPase activities were
measured in the presence of trifluoperazine, bepridil, and
cetiedil (Fig. 3). None ofthe drugs produced notable reductions
in basal Ca2+-ATPase activity at drug concentrations which
produced nearly total inhibition of CaM-stimulated activity.
At 0.3-2 nM CaM, IC"o values were 13-14 gsM trifluoperazine,
17-19 MM bepridil, and 39-53 MAM cetiedil. Precise K, deter-
minations at these drug and CaM concentrations were not
possible due to nonlinearity of these Dixon plots also (not
shown). Double reciprocal plots of these data are shown as
inserts in Fig. 3. Enzyme inhibition by all three drugs appears
to be competitive with CaM, and the y intercepts approximate
the reciprocal of the expected CaM-stimulated Ca2+-ATPase
activities, V. = 6-10 nmol Pd/mg membrane protein per
minute (19). As was found in the binding studies (Fig. 2),









Figure 2. Inhibition of Ca2+-dependent '251-CaM binding to erythro-
cyte ghost membranes by increasing concentrations of trifluoperazine,
bepridil, and cetiedil. Various concentrations of these agents were
incubated with 0.3 nM (-u,*,.), 0.8 nM (Am,0,), or 2 nM (-U,0,)
l2Sj(CaM (68,000 cpm/pmol) and erythrocyte ghost membranes (20
30 45 60 75
EPRIDIL, FM
10 30 45 60 75 90
CETIEDIL, FM
Ag protein) for 5 h before specific binding was determined (see
Methods). The insets contain linear regression analyses of the recipro-
cals of bound and unbound '251-CaM measured at each drug concen-
tration.
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Figure 3. Inhibition of CaM-stimulated erythrocyte ghost membrane
Ca2+-ATPase activity by increasing concentrations of trifluoperazine,
bepridil, and cetiedil. Various concentrations of these agents were
incubated in the absence of CaM (o) or in the presence of 0.3 (m,*,
*), 0.8 (A, m, e), or 2 nM CaM (-m, *) and erythrocyte ghost
membranes (20 ,ug protein) for 5 h before 32P-ATP (10,000-15,000
cpm/nmol) was added to 50 MM and Ca2+-dependent ATP hydrolysis
was measured (see Methods). The insets contain linear regression
analyses of reciprocals of CaM-activated Ca2+-ATPase activities (basal
subtracted) and unbound CaM concentrations (determined by paral-
lel '25IICaM binding assay, see Fig. 2) measured at each drug concen-
tration.















linear regression of double reciprocal data at higher drug
concentrations project to slightly higher y intercepts indicating
the existence of secondary, noncompetitive interactions which
produce reductions in apparent Vmax.
As expected for competitive interactions, drug inhibition
of CaM-dependent Ca2+-ATPase activity can be overcome by
increasing concentrations of CaM. 40 tM trifluoperazine, 80
MM bepridil, and 100 AM cetiedil are at or above the concen-
trations which produced nearly complete inhibition of CaM
binding (Fig. 2) and CaM-activated Ca2+-ATPase (Fig. 3).
These drug concentrations were employed in Ca2+-ATPase
assays with concentrations of CaM rising from 2 to 128 nM
(Fig. 4). In the absence of drug, 2 nM CaM stimulated the
enzyme nearly maximally. In the presence of each drug, little
CaM stimulation was measured at 2 nM CaM; however, the
inhibition was reversed with increasing CaM concentrations
and approached Vmax at 128 nM CaM.
Drugs do not damage membrane target sites for CaM. An
important consideration in these studies is to evaluate possible
nonspecific effects of these drugs on CaM target sites. The
catalytic activity of the Ca2+-ATPase in the absence of CaM is
unaffected by these drugs. Basal Ca2+-ATPase activity was only
slightly reduced by increasing concentrations of trifluoperazine,
bepridil, and cetiedil (Figs. 3 and 5). Direct effects of CaM-
inhibitory drugs upon stimulated enzyme catalytic activity
cannot be evaluated when CaM is present. However, full Ca2+-
ATPase activity can be evoked in the absence of CaM by
controlled proteolytic removal of the CaM-binding regulatory
domain of the enzyme. The resulting catalytic activity (dereg-
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Figure 4. Restoration of CaM-dependent Ca2+-ATPase activity in
erythrocyte ghost membranes incubated with trifluoperazine, bepridil,
or cetiedil by increasing concentrations of CaM. Erythrocyte ghost
membranes (24 jg protein) were incubated with increasing concen-
trations of CaM in the presence of 40 MM trifluoperazine (-), 80 AM
bepridil (v), 100 MuM cetiedil (-), or with no additional drug (o) for
2.5 h before 32P-ATP (10,000 cpm/nmol) was added to 50 MM and
Ca2+-dependent ATP hydrolysis was measured (see Methods). Basal
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Figure 5. Lack of inhibition of CaM-independent Ca2+-ATPase activ-
ities by increasing concentrations of trifluoperazine, bepridil, or cetie-
dil. Spectrin-stripped membrane vesicles were prepared from fresh
erythrocyte ghost membranes, and a portion of these were mildly
digested with a-chymotrypsin under controlled conditions (see Meth-
ods). Digested membrane vesicles (x; 13 jig protein) or undigested
membrane vesicles (o, *U, e; 18 jtg protein) were incubated with
increasing concentrations of trifluoperazine, bepridil, or cetiedil with
2 nM CaM (A, *, *) or without CaM (o, x) for 3 h before 32P-ATP
(16,000 cpm/nmol) was added to 16 juM and Ca2+-dependent ATP
hydrolysis was measured (see Methods).
resembles CaM stimulation of the intact enzyme (25). Vesicles
with proteolytically stimulated Ca2+-ATPase activity were in-
cubated with increasing concentrations of trifluoperazine, be-
pridil, and cetiedil (Fig. 5). While this range of drug concen-
trations nearly totally abolished CaM-stimulated Ca2+-ATPase
activity, the proteolytically stimulated enzyme activity was
virtually undiminished. Thus, it appears that the principal
drug inhibition of Ca2+-ATPase activity is not due to direct
interaction of the agents with the catalytic domain of the
enzyme.
Lack ofidentifiable, persistent effects ofdrugs directly upon
membrane binding sites. Preincubation experiments failed to
identify drug-membrane interactions leading to reduced 125i-
CaM binding if the membranes were washed prior to addition
of I25I-CaM. Erythrocyte membranes were incubated in buffered
Ca2+ in the absence of drug or in the presence of trifluoperazine,
bepridil, or cetiedil (Fig. 6). If '251-CaM was then added,
binding was significantly inhibited. If the membranes were
preincubated with drugs but washed in Ca2+-containing buffers
before addition of 1251-CaM, inhibition of '251-CaM binding
was no longer detected. Thus, it is unlikely that the reduced
'251-CaM binding is due to irreversible-direct Ca2+-dependent
interaction of the drugs with the membrane binding sites. It is
still conceivable that drug-membrane interactions may occur
that are rapidly and completely reversed by washing the
membranes in Ca2-containing buffers.
Bepridil and cetiedil displace [3H]trifluoperazinefrom sites
on CaM. Trifluoperazine has been shown to bind directly to
sites on CaM in the presence of Ca2 , and the number of sites
and affinity of the interactions have been measured by equilib-
rium dialysis (8). Similar [3H]trifluoperazine displacement
measurements were performed in the presence of increasing
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100 - Figure 6. Lack of persistent
CaM-binding inhibition after
washing erythrocyte mem-
80 branes previously incubated
ae /with trifluoperazine, bepridil,
d or cetiedil. Erythrocyte ghost
D 60 - membranes (2 mg protein)
0m g were incubated for 45 min at
a / room temperature in 6 ml of
40 80 mM NaCI, 30 mM KCI, 30
mM Hepes (pH 7.3), 2.50 mM
£ CaCl2/2.50 mM NaEGTA
20 (pCa2+ = 5.0), with 25 ,uM tri-
fluoperazine (A, *), 60 ,M be-
pridil (c, a), 80 1M cetiedil (o,
6 *), or no other addition (.).
2 4 6
12I-CaM,.M 0.5-ml aliquots were removed
from each tube for analysis of
Ca2+-dependent binding of 6 nM '25I-CaM (a, *, *). The remaining
membranes (a, A, o, o) were washed by dilution to 40 ml in the same
buffer, pelleted at 44,000 g for 15 min, and resuspended in 2 ml of I
mM Hepes, pH 7.3, immediately before analysis of binding 0.36,
0.96, 2.4, or 6 nM '251-CaM (see Methods). 100% bound refers to
maximum binding of 6 nM '25I-CaM by the membranes in the
unwashed and washed groups to which no additional drugs were
added during the preincubation. Significant differences are noted
between control (.) and drug-preincubated membranes in the un-
washed group (A,, , *) while no differences persist between control (-)
and drug-preincubated membranes in the group washed before addi-
tion of '25I-CaM (A, o, o).
concentrations of unlabeled trifluoperazine, bepridil, and cetiedil
(Fig. 7). All three drugs displace [3HJtrifluoperazine with the
relative potencies of trifluoperazine > bepridil > cetiedil. The
fraction of [3H]trifluoperazine displaced by bepridil and cetiedil
was less than anticipated when compared with the potencies
with which they inhibited Ca2"-dependent '25I-CaM binding
and CaM stimulation of Ca2+-ATPase. The explanation for
this is uncertain, but it may be due to interaction of bepridil
and cetiedil with sites on CaM which only partially overlap
those to which trifluoperazine binds, or due to noncompetitive
inhibition of [3H]trifluoperazine binding to CaM as was de-
scribed for displacement of 3H-W7 by prenylamine in a
preliminary report (26). The difference may also possibly result
from relatively greater nonspecific adsorption of unlabeled
bepridil and cetiedil onto dialysis membranes (resulting in
reduction in the actual bepridil or cetiedil concentrations in
solution).
Discussion
Trifluoperazine, bepridil, and cetiedil inhibited Ca2"-dependent
binding of '25I-CaM to erythrocyte membranes and inhibited
CaM activation of membrane Ca2+-ATPase with IC50 values
of -12, -17, and -40 uM, respectively. Detailed analyses
indicate that the inhibition at concentrations of up to 20 ;M
trifluoperazine, 30 MM bepridil, and 45 gM cetiedil is entirely
Figure 7. Displacement of
O 100* [3H]trifluoperazine fromz
o sites on CaM by equilib-
CIO 1\krium dialysis with increas-
z \ x ~\ ing concentrations of unla-
N ^ \ beled trifluoperazine, bepri-
5 \ dil, or cetiedil. Dialysis
o bags (0.5 ml) containing
_j sv2.5 IuM CaM and 0.5 mg
U-
gelatin or 0.5 mg gelatin
II- I , alone were dialyzed to
100 200 equilibrium by gently shak-
UNLABELED DRUG, FM ing for 15 h at room tem-
perature in the dark in
glass beakers containing 20 ml of 0.1 M Hepes, 2.50 mM CaCI2/2.50
mM NaEGTA (pCa = 5.0), 1 mM NaN3, 10 AM [3H~trifluoperazine
(80,000 cpm/ml), and also containing increasing concentrations of
unlabeled trifluoperazine (A), bepridil (i), or cetiedil (-). The bags
were snipped and aliquots from the bags containing CaM in gelatin,
the bags containing gelatin alone, and dialysis buffer were assayed for
3H in 5 ml of Beckman Ready-Solv. 100% refers to counts per
minute specifically bound to CaM (counts per minute in CaM-gelatin
bag minus counts per minute in gelatin bag = 22,500 cpm/200 Ml)
after dialysis to equilibrium against 10 MM [3H]trifluoperazine with
no additional unlabeled drug present, as described by Weiss (22).
competitive with respect to CaM. None of the three drugs
produced identifiable direct effects upon the membranes: none
produced inhibition either of basal Ca2+-ATPase or CaM-
independent (proteolytically stimulated) Ca2+-ATPase activity,
and none produced reductions in membrane-CaM binding
which persisted after membrane washing. Bepridil and cetiedil
displaced [3H]trifluoperazine from sites on CaM, although
with somewhat less potency than did unlabeled trifluoperazine.
Thus, bepridil and cetiedil possess specific CaM-inhibitory
properties which resemble those of trifluoperazine in several
ways: (a) CaM-membrane interactions are competitively inhib-
ited by these agents, (b) no effects of drugs acting directly on
membranes were identified at these concentrations, and (c) the
agents displaced trifluoperazine from sites on CaM. While
none of the experiments conclusively demonstrated inhibition
by direct interaction of bepridil or cetiedil with CaM, when
taken together, these data are most consistent with that expla-
nation. However, it is not possible to rule out secondary,
reversible interactions of the drug with membrane target sites
that result in inhibition of CaM binding. Such studies will
require purification of CaM-binding proteins and direct mea-
surements of radiolabeled drugs to these CaM-binding proteins.
Despite active clinical and physiologic interest in the
multiple effects of bepridil and cetiedil, the biochemical bases
of these effects have not been uncovered. The studies in this
report indicate that bepridil and cetiedil may deliver primary
effects by interacting with CaM leading to inhibition of CaM-
dependent enzymes. Bepridil and cetiedil act pharmacologically
and inhibit Ca2+-dependent 125I-CaM binding and CaM-acti-
vation of Ca2+-ATPase at similar concentrations. Bepridil and
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cetiedil are used clinically in Europe for the treatment of
angina and claudication, and several other beneficial cardio-
vascular effects have been noted in experimental animals (27-
32). Although most are preliminary, several recent reports
noted very encouraging antianginal (33, 34) and antiarrhythmic
results (35-39) in clinical studies with bepridil. Some of these
benefits may be derived from inhibition of CaM-regulated
myosin light chain kinase in vascular smooth muscle. Other
effects may result from bepridil and cetiedil acting directly on
cardiac muscle which contains large amounts of CaM in
addition to troponin C, a related protein. CaM exists in all
eukaryotic tissues, and not surprisingly, micromolar concen-
trations of bepridil and cetiedil inhibit numerous other Ca2+-
dependent processes in a variety of tissues. Bepridil reduces
Ca2l-dependent target cell lysis by Entamoeba histolytica (40).
Cetiedil inhibits Ca2+-induced cation fluxes in erythrocytes
(41) and may be of value in sickle cell disease (42-44). Cetiedil
was found to inhibit CaM-stimulated brain phosphodiesterase
and erythrocyte Ca2+-ATPase (45, 46) and specifically modu-
lates certain Ca2+-dependent polymorphonuclear leukocyte
functions (47) and platelet aggregation. While it is likely that
some of these effects may result from inhibition of CaM-
dependent enzymes or CaM binding proteins, other CaM-
inhibitors have been found to inhibit additional Ca2+-sensitive
enzymes in the absence ofCaM, such as protein kinase C (48-
50) and phosphatase Ilb (51). Several other proteins bound
directly to phenothiazine columns in the presence of Ca2l
even though they did not contain CaM subunits and failed to
bind to CaM-affinity columns (52). Thus, it is likely that
certain effects of bepridil and cetiedil are not due to inhibition
of CaM.
Bepridil and cetiedil may belong to a new class of vascular
smooth muscle relaxants which achieve their principal phar-
macologic effects by inhibition of CaM and other intracellular
Ca2+-sensitive processes rather than by direct interaction with
the Ca2+ channels which regulate Ca2+ entry. Therefore, bepridil
and cetiedil are different from the recognized Ca2" channel
blockers (although some of the latter have also been
found to interact with CaM) (53-55). Certain other smooth
muscle relaxants with related structures including naphtha-
lenesulfonamides (W7 and No. 233) and prenylamine (another
European coronary vasodilator) interact directly with CaM
with comparable affinities, inhibit CaM-activated myosin light
chain kinase (12), and may also be considered members of
this class of drugs. These agents all appear to achieve at least
some of their principal pharmacologic effects by inhibition of
CaM-dependent enzymes. These agents are also distinct from
phenothiazines, which produce their principal antipsychotic
effects at very low concentrations by interaction with dopamine
receptors but produce side effects at higher concentrations
probably due to interaction with CaM.
All tissues contain CaM, and since many CaM-dependent
enzymes are essential for cell survival, it appears paradoxical
that unselective inhibition of CaM is not deleterious. CaM
inhibitors have been demonstrated to inhibit progression in
the cell cycle from GI to DNA-S phase (56). Erythrocyte
Ca2+-ATPase is inhibited by phenothiazines (57), and accu-
mulation of intracellular Ca2" can produce toxic activation of
intracellular proteases (58) and transglutaminase (59). Therefore,
for CaM inhibition to be clinically useful, there must be
inhibition of certain enzymes more than others. Selective
inhibition may result from differences in drug levels in different
tissues or even by enzyme localizations within a cell. It is also
likely that the affinity with which CaM activates certain
enzymes may be important in selective enzyme inhibition.
The system described in this report may be useful for identi-
fication and evaluation of selective CaM inhibitors.
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